A new dimension in drug discovery: reversing epithelial–mesenchymal transition (EMT)

EMT: 2016

(2016) M. Angela Nieto et al.   CELL

Droplet-based microfluidics in drug discovery, transcriptomics and high-throughput molecular genetics

(2016) Nachiket Shembekar et al.   LAB ON A CHIP

Epithelial–mesenchymal transition: a new target in anticancer drug discovery

(2016) Fabrizio Marcucci et al.   NATURE REVIEWS DRUG DISCOVERY

GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification

(2016) Vin Yee Chung et al.   Scientific Reports

Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition

(2013) M. Yu et al.   SCIENCE

An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530)

(2013) R Y-J Huang et al.   Cell Death & Disease

Metastatic Colonization Requires the Repression of the Epithelial-Mesenchymal Transition Inducer Prrx1

(2012) Oscar H. Ocaña et al.   CANCER CELL

Screening therapeutic EMT blocking agents in a three-dimensional microenvironment

(2012) Amir R. Aref et al.   Integrative Biology

Target cell movement in tumor and cardiovascular diseases based on the epithelial–mesenchymal transition concept

(2011) Kian-Ngiap Chua et al.   ADVANCED DRUG DELIVERY REVIEWS

The transcription factor grainyhead-like 2 regulates the molecular composition of the epithelial apical junctional complex

(2010) M. Werth et al.   DEVELOPMENT